Last year, the FDA approved the use of a drug derived from CBD to treat a rare form of pediatric epilepsy. Even with such regulatory action, the scientific community has been unsure about the way food promotes or hinders the absorption of CBD taken orally into the body. This question prompted researchers at the University of Minnesota to conduct a clinical trial to examine whether eating a meal high in fat could improve the rate at which one’s body absorbed orally administered CBD.
The researched measured the amount of CBD that could be detected in the blood of patients at an epilepsy care clinic. The capsules the patients were taking contained CBD with a 99 percent purity.
The researchers then gave some patients a standardized high-fat breakfast before they took their CBD medication while another group took the medication on an empty stomach. CBD concentrations in the blood of the individuals in these two groups were measured.
The study discovered that the detectable CBD in the blood of patients increased four-fold if those patients ate a fatty meal before ingesting the drug. In some patients, the increase in absorption of CBD was as high as 14 times what was registered in those who didn’t eat anything before taking the CBD capsules.
The researchers also found that there was no difference in the cognitive function markers of the two groups of patients despite one group having higher CBD levels in their blood. This finding is similar to what other studies have shown that CBD has no effect on cognitive function, unlike THC which can impair one’s cognitive abilities.
The study authors conclude that the meals a person has can affect the concentration of CBD in their blood, so adjustments need to be made to patients’ diets in order to ensure that CBD remains at the desired concentration in the bloodstream in order to initiate the therapeutic impact that is required.
The study findings were published in the journal Epilepsia and they are expected to trigger modifications to the advice or instructions that patients are given as they take CBD as a sole or complementary form of medication for different ailments and conditions.
According to industry analysts, the CBD industry and all its players like Grapefruit Boulevard Investments Inc. (OTCQB: IGNG) and Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) are likely to welcome this research because it brings clarity on how patients can maximize the benefits they get from CBD treatments. The total cost of treatment could also go down since more can be achieved by modifying one’s diet in order to increase CBD absorption rates.
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have a questions or are you interested in working with CNW? Ask Our Editor